Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Carbon disulfide – monoxide – or dioxide
Reexamination Certificate
2006-03-14
2006-03-14
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Carbon disulfide, monoxide, or dioxide
C424S450000, C424S484000, C424S488000, C514S058000, C514S141000, C514S165000, C514S184000, C514S185000, C514S186000, C514S188000, C514S189000, C514S492000, C514S501000, C514S502000, C514S505000, C514S569000, C514S605000, C514S824000, C514S825000, C514S826000, C514S879000, C514S886000, C514S887000, C514S894000, C514S903000, C514S921000, C514S950000, C514S958000, C514S959000, C514S964000
Reexamination Certificate
active
07011854
ABSTRACT:
Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
REFERENCES:
patent: 4657902 (1987-04-01), Kappas et al.
patent: 4699903 (1987-10-01), Rideout et al.
patent: 5086060 (1992-02-01), Haley et al.
patent: 5102670 (1992-04-01), Abraham et al.
patent: 5447939 (1995-09-01), Glasky et al.
patent: 5621000 (1997-04-01), Arena et al.
patent: 5664563 (1997-09-01), Schroeder et al.
patent: 5670664 (1997-09-01), Kao et al.
patent: 5700947 (1997-12-01), Soldato
patent: 5861426 (1999-01-01), Del Soldato et al.
patent: 5882674 (1999-03-01), Herrmann et al.
patent: 5885621 (1999-03-01), Head et al.
patent: 5888982 (1999-03-01), Perrella et al.
patent: 5891689 (1999-04-01), Takle et al.
patent: 6040341 (2000-03-01), Del Soldato et al.
patent: 6051576 (2000-04-01), Ashton et al.
patent: 6066333 (2000-05-01), Willis et al.
patent: 6203991 (2001-03-01), Nabel et al.
patent: 6218417 (2001-04-01), Del Soldato
patent: 6242432 (2001-06-01), Del Soldato
patent: 2002/0155166 (2002-10-01), Choi et al.
patent: WO91/01128 (1991-02-01), None
patent: WO95/05814 (1995-03-01), None
patent: WO95/09831 (1995-04-01), None
patent: WO96/09038 (1996-03-01), None
patent: WO97/16405 (1997-05-01), None
patent: WO98/29115 (1998-07-01), None
patent: WO98/48848 (1998-11-01), None
patent: WO99/67231 (1999-12-01), None
patent: WO00/56743 (2000-09-01), None
patent: WO00/61537 (2000-10-01), None
patent: WO01/12584 (2001-02-01), None
patent: WO02/078684 (2002-10-01), None
patent: WO02/092072 (2002-11-01), None
patent: WO02/092075 (2002-11-01), None
patent: WO03/000114 (2003-01-01), None
Chemical Abstracts 141:270758 (2004).
Chemical Abstracts 140:40075 (2004).
Chemical Abstracts 142:211995 (2004).
Chemical Abstracts 137:119662 (2002).
Choi et al., US Publication No. 2002 0155166 A1; Publication Date Oct. 24, 2002.
Motterelini et al.; Carbon Monoxide—Releasing Molecules Characterization of Biochemical and Vascular Activities; Circ. Res. 2002, 90:e17-e24.
Motterlini et al; Studies on the development of carbon monoxide-releasing molecules: potential applications for the treatment of cardiovascular dysfunction; CRC Press, New York, 2002; pp. 249-272—Rui Wang Editor.
Hans-Jochen Meder and Wolfgang Beck (1986) Metallkomplexe mit biologisch wichtigen liganden, XLII(1) carbonylmetallkomplexe mit anionen von mehrfunktionellen a-aminosaueren. Zeitschrift fuer Naturforschung 41b, 1247-1254.
Ivana Verona et al. (1996) Regloselectivity in the nucleophilic functionalization of dibenzofuran, dibezothiophene and xanthene complexes of Mn(CO)3+; Journal of Organometallic Chemistry 524, 71-80.
Clark et al.; (2003); Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule; Circ. Res. 93:e2-8.
Johnson et al.; (2003) Metal carbonyls; a new class of pharmaceuticals; Angew Chem Int Ed Engl 42:722-3729.
Motterlini et al.; (2003) Bioactivity and pharmacologial actions of carbon monoxide-releasing molcules; Curr. Pharm Des 9:2525-2539.
Stanford et al. (2003) Heme oxygenase is expressed in human pulmonary artery smooth muscle where carbon momoxide has an anti-proliferative role; Eur. J. Pharmacol. 473:135-141.
Ozawa et al.; (2002) Leydig cell-derived heme-oxygenase-1 regulates apoptsis of premelotic germ cells in response to stress; J clin Invest 109:457-467.
Chauveau et al.; (2002) Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection; Am J Transplant 2:582-592.
International Search Report in corresponding PCT application No. PCT/IB03/00932.
Otterbein Leo E et al; “Carbon Monoxide Has Anti-Inflammatory Effects Involving the Mitogen-Activated Protein Kinase Pathway”Nature Medicine; vol. 6, No. 4 (Apr. 2000), pp. 422-428.
Fernandes Ana Cristina
Goncalves Isabel
Haas Werner
Romao Carlos
Roya Beatriz
Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos
Pak John
LandOfFree
Method for treating a mammal by administration of a compound... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a mammal by administration of a compound..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a mammal by administration of a compound... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3595709